Cyclooctanesulfonyl chloride | 62371-32-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 磺酰卤
• 英文名称: Cyclooctanesulfonyl chloride
• CAS: 62371-32-8
• 化学式: C₈H₁₅ClO₂S
• 分子量: 210.72
• InChiKey: RXRGHUGKLXISSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• URICOSURIC AGENT
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP0788796A1

  公开（公告）日：1997-08-13

  A remedy for hyperuricemia which comprises a hydantoin derivative represented by general formula (I) or a salt thereof as the active ingredient, wherein Q represents cyclohexyl, cycloheptyl, cyclooctyl, 2,5-dimethylthien-3-yl, indan-2-yl or 2,5-dichlorophenyl. The uricosuric agent exerts a potent uricosuric effect on an animal experiment model while sustaining or gradually increasing the urine volume. Further, it has a low toxicity. Thus it is useful in the treatment of hyperuricemia or in the treatment and prevention of gout. It is expected that the effect of the uricosuric agent of sustaining or gradually increasing the urine volume would relieve the load on a patient of taking a large amount of water.

  一种治疗高尿酸血症的药物，包括以通式（I）表示的噻唑环衍生物或其盐作为活性成分，其中Q代表环己基、环庚基、环辛基、2,5-二甲基噻吩-3-基、茚基或2,5-二氯苯基。这种利尿药在动物实验模型中表现出强效的利尿作用，同时维持或逐渐增加尿量。此外，它具有低毒性。因此，在治疗高尿酸血症或痛风的治疗和预防中具有用处。预计利尿药维持或逐渐增加尿量的作用将减轻患者摄入大量水的负担。
• PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20210246117A1

  公开（公告）日：2021-08-12

  The disclosure provides processes for preparing a compound of Formula (I).

  该披露提供了制备化合物式（I）的过程。
• Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
  申请人：Lubisch Wilfried

  公开号：US20070021607A1

  公开（公告）日：2007-01-25

  The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R 3 , R 4 , R 5 , R 6 and R 7 are defined according to claim 1 , and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivaties can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

  本发明涉及公式(I)的新型1,3-二氢吲哚-2-酮(氧吲哚)衍生物，其中A、R3、R4、R5、R6和R7根据权利要求1所定义，并且含有这些衍生物的药物可用于治疗疾病。特别是，这些新型氧吲哚衍生物可用于控制和/或预防各种依赖于血管加压素或催产素的疾病。
• PROCESS FOR PRODUCING ACID ANHYDRIDE
  申请人：Tokuyama Corporation

  公开号：EP1413572A1

  公开（公告）日：2004-04-28

  According to the present invention there is provided a process for producing an acid anhydride by reacting a carboxylic acid, preferably a carboxylic acid having a polymerizable group, with a sulfonyl halide compound in the presence of a tertiary amine or in the presence of a tertiary amine and an inorganic base, wherein the tertiary amine or the tertiary amine and the inorganic base are used in an amount of 0.9 to 1.2 equivalents relative to the acid generated from the sulfonyl halide compound.

  根据本发明，提供了一种生产酸酐的工艺，其方法是在叔胺存在下或在叔胺和无机碱存在下，使羧酸（最好是具有可聚合基团的羧酸）与磺酰卤化合物反应，其中叔胺或叔胺和无机碱的用量相对于磺酰卤化合物生成的酸为 0.9 至 1.2 个当量。
• Process for production of acid anhydride
  申请人：——

  公开号：US20040242929A1

  公开（公告）日：2004-12-02

  According to the present invention there is provided a process for producing an acid anhydride by reacting a carboxylic acid, preferably a carboxylic acid having a polymerizable group, with a sulfonyl halide compound in the presence of a tertiary amine or in the presence of a tertiary amine and an inorganic base, wherein the tertiary amine or the tertiary amine and the inorganic base are used in an amount of 0.9 to 1.2 equivalents relative to the acid generated from the sulfonyl halide compound.

  根据本发明，提供了一种生产酸酐的工艺，其方法是在叔胺存在下或在叔胺和无机碱存在下，使羧酸（最好是具有可聚合基团的羧酸）与磺酰卤化合物反应，其中叔胺或叔胺和无机碱的用量相对于磺酰卤化合物生成的酸为 0.9 至 1.2 个当量。